Insomnia is a sleep disorder with difficulty falling asleep or staying asleep, early awakening and so on. It is also the most common complaints in primary ...
To help protect access to medicines for cancer and rare disease patients, AstraZeneca has filed a legal challenge to critical aspects of the drug pri...
Gilead Sciences, Inc. (Nasdaq: GILD) announced that the U.S. Food and Drug Administration (FDA) approved a supplemental new drug application (sNDA) f...
The HD-MAP platform technology offers user-friendly vaccines, allowing possible self-administration. Its room temperature stability revolutionizes distri...
Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), announced that its IoNovo Iodine product has been gr...
One in Four American Adults Would Rather Not Know They Have Cancer A new study from The Harris Poll, commissioned by Bayer, suggests fear factors ...
Illumina's expansion comes after 16 years of working closely with the company's channel partner in India, Premas Life Sciences. Now with its own permanent ...
TARPEYO is currently approved under accelerated approval to reduce proteinuria in adults with primary IgA nephropathy (IgAN) at risk of rapid disease progr...
3Z, holds expertise in developing genetically engineered models of central nervous system disorders, has successfully identified potential ADHD treatments ...
FLAURA2 data reinforce TAGRISSO® as backbone therapy for EGFR-mutated advanced lung cancer in combination with chemotherapy; granted Breakthrough Thera...
TAE Life Sciences has announced a landmark agreement with Biddle Sawyer to serve as the exclusive supplier of TC220, a novel boronated amino aci...
Koneksa, a healthcare technology company pioneering evidence-based digital biomarkers, today announced the first collaboration in the Koneksa Academic Part...
ZetaMet™ is a first-of-its kind molecular pathway designed to suspend cancer, inhibit pain, and regenerate bone. ZetaMet™ is presently i...
Acquisition of Chinook Therapeutics, a clinical-stage biopharmaceutical company, completed for USD 3.2bn upfront Deal brings two phase 3 assets in d...
© 2024 Biopharma Boardroom. All Rights Reserved.
